4.8 Article

A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy

Journal

EMBO JOURNAL
Volume 22, Issue 24, Pages 6471-6482

Publisher

WILEY
DOI: 10.1093/emboj/cdg637

Keywords

angiotensin II; AT(2) receptor; cardiac hypertrophy; PLZF; transcription factor

Funding

  1. NCI NIH HHS [P30 CA068485, CA-68485] Funding Source: Medline
  2. NHLBI NIH HHS [R01 HL058205, HL-58205, R37 HL058205] Funding Source: Medline
  3. NIDDK NIH HHS [DK-20593, P60 DK020593, P30 DK020593] Funding Source: Medline

Ask authors/readers for more resources

We describe a novel signaling mechanism mediated by the G-protein-coupled receptor (GPCR) angiotensin II (Ang II) type 2 receptor (AT(2)). Yeast two-hybrid studies and affinity column binding assay show that the isolated AT(2) C-terminus binds to the transcription factor promyelocytic zinc finger protein (PLZF). Cellular studies employing confocal microscopy show that Ang II stimulation induces cytosolic PLZF to co-localize with AT(2) at the plasma membrane, then drives AT(2) and PLZF to internalize. PLZF slowly emerges in the nucleus whereas AT(2) accumulates in the perinuclear region. Nuclear PLZF binds to a consensus sequence of the phosphatidylinositol-3 kinase p85alpha subunit (p85alpha PI3K) gene. AT(2) enhances expression of p85alpha PI3K followed by enhanced p70(S6) kinase, essential to protein synthesis. An inactive mutant of PLZF abolishes this effect. PLZF is expressed robustly in the heart in contrast to many other tissues. This cardiac selective pathway involving AT(2), PLZF and p85alpha PI3K may explain the absence of a cardiac hypertrophic response in AT(2) gene-deleted mice.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available